City hospital # 1
Arkhangelsk, Arkhangelskaya oblast, 163000, Russia
NCT Number: NCT06332768
The weaning failure is a paramount challenge when aggressive discontinuation of respiratory support in ARDS. The aim of the study is to improve weaning safety and efficacy by a transient postextubation non-invasive respiratory support.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Arkhangelsk, Arkhangelskaya oblast, 163000, Russia
HFNO (high-flow nasal oxygenation and NIV (non invasive ventilation) are to be randomly compared in the ARDS postextubation period.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
ARDS
Exclusion criteria
Severe ICU-aquired weakness Severe COPD
High-flow nasal oxygenation
Other names: Oxygenation
Time frame: 48 hrs
Weaning failure and re-intubation or recanulation
Northern State Medical University
Other
Comparison of High Flow Oxygenation, Noninvasive Ventilation and Standard Oxygen Therapy in the Early Post-extubation Period in Patients With Acute Respiratory Distress Syndrome
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05650957
Acute Respiratory Distress Syndrome, COVID-19
La Plata, Argentina
View Trial DetailsNCT06224010
ARDS, Human, Acute Hypoxic Respiratory Failure
Turin, Italy
View Trial DetailsNCT04818164
Acute Respiratory Distress Syndrome, Coronaviridae Infections
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06014138
Acute Respiratory Distress Syndrome, Lung Diseases
London, United Kingdom
View Trial Details